Last reviewed · How we verify
Testagen® TDS Testosterone 5% HypoSpray® — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Testagen® TDS Testosterone 5% HypoSpray® (Testagen® TDS Testosterone 5% HypoSpray®) — Transdermal Delivery Solutions Corp.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Testagen® TDS Testosterone 5% HypoSpray® TARGET | Testagen® TDS Testosterone 5% HypoSpray® | Transdermal Delivery Solutions Corp | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Testagen® TDS Testosterone 5% HypoSpray® CI watch — RSS
- Testagen® TDS Testosterone 5% HypoSpray® CI watch — Atom
- Testagen® TDS Testosterone 5% HypoSpray® CI watch — JSON
- Testagen® TDS Testosterone 5% HypoSpray® alone — RSS
Cite this brief
Drug Landscape (2026). Testagen® TDS Testosterone 5% HypoSpray® — Competitive Intelligence Brief. https://druglandscape.com/ci/testagen-tds-testosterone-5-hypospray. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab